Cargando…

A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model

BACKGROUND: Invasive pulmonary aspergillosis (IPA) is a life-threatening disease in immunosuppressed patients. Voriconazole is commonly used to prevent and treat IPA in the clinic, but the optimal prophylactic antifungal regimen is unknown. The objective of this study was to clarify the mechanism un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Taotao, Zhang, Tao, Meng, Ti, Li, Ying, Chen, Lu, Yang, Qianting, Dong, Haiyan, Lei, Jin’e, Chen, Limei, Dong, Yalin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992762/ https://www.ncbi.nlm.nih.gov/pubmed/29880050 http://dx.doi.org/10.1186/s12967-018-1533-4

Ejemplares similares

Voriconazole-refractory invasive aspergillosis
por: Park, Se Yoon, et al.
Publicado: (2017)

Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis
por: Jiang, Zhiwen, et al.
Publicado: (2022)

Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis
por: Maertens, Johan A., et al.
Publicado: (2023)

Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses
por: Kuroda, Taisuke, et al.
Publicado: (2021)

The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib
por: Nyga, Rémy, et al.
Publicado: (2019)

Management of invasive aspergillosis in patients with COPD: Rational use of voriconazole
por: Ader, Florence, et al.
Publicado: (2009)

Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic/Pharmacodynamic Modeling and Monte Carlo Simulation
por: Alqahtani, Saeed, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Determination of Systemic MIC Breakpoints for Intermittent, Extended, and Continuous Infusion Dosage Regimens of Mecillinam
por: Koumaki, Vasiliki, et al.
Publicado: (2023)

Predicting the Outcome of Voriconazole Individualized Medication Using Integrated Pharmacokinetic/Pharmacodynamic Model
por: Yang, Ping, et al.
Publicado: (2021)

Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature
por: Sandherr, M, et al.
Publicado: (2011)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

The recommended dosage regimen for caspofungin in patients with higher body weight or hypoalbuminaemia will result in low exposure: Five years of data based on a population pharmacokinetic model and Monte-Carlo simulations
por: Yang, Qianting, et al.
Publicado: (2022)

Short course of voriconazole therapy as a risk factor for relapse of invasive pulmonary aspergillosis
por: Shin, Dong Hoon, et al.
Publicado: (2020)

Optimization and Validation of Dosage Regimen for Ceftiofur against Pasteurella multocida in Swine by Physiological Based Pharmacokinetic–Pharmacodynamic Model
por: Mi, Kun, et al.
Publicado: (2022)

Orbital Aspergillosis: Voriconazole – The New Standard Treatment?
por: Ohlstein, Derek H., et al.
Publicado: (2012)

Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies
por: Krueger, Kem P, et al.
Publicado: (2009)

An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole
por: Jacobs, F., et al.
Publicado: (2011)

Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain
por: Grau, Santiago, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs
por: Seo, Do‐Hyun, et al.
Publicado: (2018)

1147. Short Course of Voriconazole Therapy as a Risk Factor for Relapse of Invasive Pulmonary Aspergillosis
por: Shin, Dong Hoon, et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
por: Leelawattanachai, Pannee, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
por: Harrington, Rachel, et al.
Publicado: (2016)

Voriconazole: Lack of efficacy during treatment of invasive pulmonary aspergillosis: 2 case reports
Publicado: (2021)

Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis
por: Sarfati, Sacha, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients
por: Han, Ruiying, et al.
Publicado: (2021)

Evaluating a tylosin dosage regimen for treatment of Staphylococcus delphini infection in mink (Neovison vison): a pharmacokinetic-pharmacodynamic approach
por: Ronaghinia, Amir Atabak, et al.
Publicado: (2021)

Voriconazole-Induced Hepatotoxicity in a Patient with Pulmonary Aspergillosis: A Case Report
por: Gu, Li, et al.
Publicado: (2023)

Safety, Efficacy, and Exposure–Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis
por: Martin, Judith M., et al.
Publicado: (2017)

1566. Population Pharmacokinetics of Voriconazole: Serum Albumin Status as a Novel Marker of Clearance and Dosage Optimization
por: Chantharit, Prawat, et al.
Publicado: (2019)

Invasive maxillary sinus aspergillosis: A case report successfully treated with voriconazole and surgical debridement
por: Peral-Cagigal, Beatriz, et al.
Publicado: (2014)

Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis
por: Martínez-Casanova, Javier, et al.
Publicado: (2018)

Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden
por: Floros, Lefteris, et al.
Publicado: (2019)

Dexamethasone/voriconazole: Invasive aspergillosis following off-label use; lack of efficacy: case report
Publicado: (2022)

Immunosuppressants/voriconazole: COVID-19 infection, invasive systemic aspergillosis and visual disturbance: case report
Publicado: (2021)

Dexamethasone/voriconazole: Invasive pulmonary aspergillosis secondary to Aspergillus terreus and treatment failure: case report
Publicado: (2021)

Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study
por: Kim, Sun Bean, et al.
Publicado: (2017)

Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats
por: Shen, Jiquan, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic integration for optimal dosage of cefquinome against Streptococcus equi subsp. equi in foals
por: Lee, Dong-Ha, et al.
Publicado: (2020)

Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial
por: Cadranel, J., et al.
Publicado: (2012)

Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine Streptococcus suis infection
por: Luo, Wanhe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0qp04nvpeegs5fhb86nib0a09f